Administrative Core
行政核心
基本信息
- 批准号:10696955
- 负责人:
- 金额:$ 10.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-15 至 2026-07-31
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVAcute Lung InjuryAcute Respiratory Distress SyndromeAdvisory CommitteesAlveolarAlveolar MacrophagesAnimalsCD4 Positive T LymphocytesCD8-Positive T-LymphocytesCOVID-19Cause of DeathCell modelCellsCessation of lifeClinicalCollaborationsCommittee MembersCommunicationCytoprotectionDevelopmentDiseaseDistalEconomicsEpithelial CellsEtiologyFailureFeedbackFosteringFunctional disorderFunding OpportunitiesHospitalizationHuman ResourcesHypoxemiaImmuneImmune responseImmunologicsInfectionInflammationInflammatoryInfluenza A virusInformation DisseminationInstitutionInstructionInterdisciplinary StudyLinkLower Respiratory Tract InfectionLower respiratory tract structureLungLymphocyteOrganOutcomePathogenesisPathogenicityPathway interactionsPatientsPhasePlayPneumoniaPopulationPostdoctoral FellowProcessPublicationsPulmonary InflammationReagentRecoveryResearchResearch PersonnelResolutionResource SharingResourcesRespiratory FailureRoleSamplingServicesStructureSupportive careTechniquesTestingTidal VolumeTissuesUnited StatesViral Load resultViral PneumoniaVirusWorkacute hypoxemic respiratory failureburden of illnesscollaborative environmentcommunity acquired pneumoniaeconomic costexperimental studyindividualized medicineinnovationlung developmentlung injurylung repairmonocytemouse modelneutrophilnovel therapeutic interventionparticipant enrollmentprogramsrecruitrepairedresiliencestudent mentoringtissue repairventilation
项目摘要
PROJECT SUMMARY_CORE A
Recovery from viral pneumonia is a clinically important yet understudied process. Severe viral pneumonia due
to influenza A virus (IAV) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiologic agent
of coronavirus disease 2019 (COVID-19), damages the lower respiratory tract to cause acute respiratory distress
syndrome (ARDS). While acute hypoxemic respiratory failure is a defining clinical feature in patients with ARDS,
advances in supportive care allow most patients to survive the hypoxemic phase of their illness. As a result, the
vast majority of patients with ARDS die from multiple organ dysfunction, including persistent respiratory failure,
days to weeks after the initial infection. Other than avoidance of additional lung injury, via low tidal volume
ventilation and a handful of other supportive therapies, there are no specific therapies for patients with viral
pneumonia/ARDS. A central hypothesis of this PPG is that the persistence of respiratory failure and the
development of multiple organ dysfunction in patients with ARDS is a consequence of the failure of normal
mechanisms of inflammation resolution and lung tissue repair. This hypothesis is clinically supported by a recent
analysis of patients enrolled in the ARDSnet where a “hyperinflammatory” endotype of ARDS patients was
associated with poor clinical outcomes, including death. We propose to investigate the process of recovery
from viral pneumonia with a focus on mechanisms that promote resolution of lung inflammation and
healthy repair of lung damage. Core A will assist the PPG investigators as they test this central hypothesis of
this PPG through a highly integrated and innovative set of experiments by focusing on five Specific Aims:
Specific Aim 1. To support communication between the Project Investigators, the Core Leaders, Collaborating
investigators, and the Internal and External Advisory Committee members.
Specific Aim 2. To provide a structure for the sharing of materials and dissemination of information between the
Project Investigators, Core Leaders and their Collaborators.
Specific Aim 3. To provide financial and regulatory oversight to the Project and Core Leaders and coordinate
their interactions with Institutional Core Services.
Specific Aim 4. To disseminate the discoveries made by the program project investigators through publications,
presentations and the sharing of resources to other institutions and other investigators.
Specific Aim 5. To foster an environment of collaborative interdisciplinary research and mentoring of students,
post-doctoral fellows and investigators.
项目概要a
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KAREN M RIDGE其他文献
KAREN M RIDGE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KAREN M RIDGE', 18)}}的其他基金
Project 1: Vimentin regulates host response and repair mechanisms to influenza A viral pneumonia
项目1:波形蛋白调节宿主对甲型流感病毒性肺炎的反应和修复机制
- 批准号:
10269674 - 财政年份:2021
- 资助金额:
$ 10.96万 - 项目类别:
Project 1: Vimentin regulates host response and repair mechanisms to influenza A viral pneumonia
项目1:波形蛋白调节宿主对甲型流感病毒性肺炎的反应和修复机制
- 批准号:
10696962 - 财政年份:2021
- 资助金额:
$ 10.96万 - 项目类别:
Vimentin-mediated regulation of the inflammasome in acute lung injury
波形蛋白介导的急性肺损伤炎症小体的调节
- 批准号:
9251880 - 财政年份:2016
- 资助金额:
$ 10.96万 - 项目类别:
Role of vimentin in influenza A-induced acute lung injury
波形蛋白在甲型流感引起的急性肺损伤中的作用
- 批准号:
8775974 - 财政年份:2014
- 资助金额:
$ 10.96万 - 项目类别:
相似海外基金
Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
急性肺损伤和急性呼吸窘迫综合征的治疗
- 批准号:
8429041 - 财政年份:2011
- 资助金额:
$ 10.96万 - 项目类别:
Analysis of extravascular lung water dynamics and exhaustive evaluation of pulmonary epithelial metabolites to establish a novel therapeutic approach for acute lung injury/ acute respiratory distress syndrome
分析血管外肺水动力学和详尽评估肺上皮代谢物,以建立急性肺损伤/急性呼吸窘迫综合征的新治疗方法
- 批准号:
22592023 - 财政年份:2010
- 资助金额:
$ 10.96万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
OBSERVATIONAL STUDY OF ACUTE LUNG INJURY & ACUTE RESPIRATORY DISTRESS SYNDROME
急性肺损伤的观察性研究
- 批准号:
7603766 - 财政年份:2007
- 资助金额:
$ 10.96万 - 项目类别:
Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
急性肺损伤和急性呼吸窘迫综合征的治疗
- 批准号:
8328484 - 财政年份:2005
- 资助金额:
$ 10.96万 - 项目类别:
Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
急性肺损伤和急性呼吸窘迫综合征的治疗
- 批准号:
8328493 - 财政年份:2005
- 资助金额:
$ 10.96万 - 项目类别:
Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
急性肺损伤和急性呼吸窘迫综合征的治疗
- 批准号:
8602427 - 财政年份:2005
- 资助金额:
$ 10.96万 - 项目类别:
Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
急性肺损伤和急性呼吸窘迫综合征的治疗
- 批准号:
8844846 - 财政年份:2005
- 资助金额:
$ 10.96万 - 项目类别:
Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
急性肺损伤和急性呼吸窘迫综合征的治疗
- 批准号:
8602351 - 财政年份:2005
- 资助金额:
$ 10.96万 - 项目类别:
Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
急性肺损伤和急性呼吸窘迫综合征的治疗
- 批准号:
8654999 - 财政年份:2005
- 资助金额:
$ 10.96万 - 项目类别:
Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
急性肺损伤和急性呼吸窘迫综合征的治疗
- 批准号:
8020428 - 财政年份:2005
- 资助金额:
$ 10.96万 - 项目类别: